Work

Searching for therapeutic strategies in a mouse modelo of Machado-Joseph disease: targeting proteostases

Year: 2015
Type: dissertation
Abstract: Machado-Joseph Disease (MJD) belongs to the group of nine Polyglutamine (PolyQ) diseases, which are characterized by the appearance of misfolded protein species, protein aggregates, neuronal dysfunction and ultimately cell death, of which is triggered by the presence of an expanded CAG repeat in the respective disease-causing genes. Along with the pathogenic motif, all these disease-associated proteins are widely expressed but the diseases only affect specific subsets of neurons. So far there is no effective treatment available for these disorders. Because the pathogenic mechanism(s) underlying MJD are poorly understood, which might be hampering the progression of effective therapeutical targets, this work focused on the search for new therapies based on hypotheses, that additionally allow the study of molecular mechanism(s) of disease. For this, we used the CMVMJD135 mouse model, which recapitulates the human disease both at the phenotypic and neuropathologic levels. We tested the efficacy of several compounds acting on different aspects of cellular function: (i) molecular chaperone load, (Hsp90 inhibitor - 17-dimethyl aminoethylamino-17-demethoxygeldanamycin hydrochloride - 17-DMAG); (ii) autophagy (lithium chloride and a combination of lithium chloride – LiCl - and temsirolimus - CCI-779); (iii) Endoplasmic reticulum (ER) stress response, (taroursodeoxycholic acid - TUDCA), also known to have multiple actions in the cells, and (iv) the energy status in the cell (creatine). \nChronic treatment of CMVMJD mice with 17-DMAG resulted in a delay in progression of the motor coordination deficits and a reduction in neuropathology. While we observed limited induction of heat-shock proteins with treatment, we found evidence that 17-DMAG could be acting through autophagy, as levels of LC3-II and beclin-1 were induced in the brain of treated animals. This resulted in decreased levels of the mutant ataxin-3 (ATXN3) and reduced intranuclear aggregation of this protein. To further test autophagy induction as potential therapeutic approach for MJD, we tested LiCl alone and a combination of LiCl with CCI-779 (m-TOR independent and dependent inducers, respectively). In spite of activating autophagy, as suggested by the increased levels of Beclin-1, Atg7, and LC3- II, and a reduction in the p62 protein levels, lithium had no overall beneficial effects in MJD model concerning motor performance. Furthermore, the combined therapy using LiCl and CCI-779 proved to be deleterious to both WT and transgenic animals, failing to rescue their neurological symptoms in the first and exerting in neurotoxic effects in the latter. \nTUDCA is an orally bioavailable and BBB permeable bile acid with known neuroprotective action, through its anti-amyloidogenic and chemical chaperone activities and its ability to modulate apoptotic pathways. In addition, TUDCA is FDA-approved for chronic use in humans to treat liver disorders, but has also been shown to be beneficial in several models of different neurodegenerative diseases. In the CMVMJD135 model, TUDCA delayed the onset of disease and improved the motor phenotype, including balance, motor coordination and gait parameters, and ameliorated neurological reflexes, exploratory movement deficits and muscular strength problems. Although TUDCA treatment did not reduce the ATXN3 aggregate load in the brain, it normalized the RNA levels of TNF-α, Il1β and Il10 in the brainstem and reduced the astrogliosis in the substantia nigra and brainstem. These results demonstrated the therapeutic efficacy of TUDCA supplementation for MJD, most likely mediated by its anti-inflammatory properties, making this compound an attractive for the treatment of neurodegenerative diseases, including MJD.Lastly, we tested the efficacy of creatine, another naturally-occurring compound known to balance energy status in the cell. Creatine-supplemented diet led to an overall improvement in the motor phenotype of CMVMJD135 mice, namely improved motor coordination, limb strength and gait quality, and amelioration of some neurological parameters such as tremors and abnormal reflexes. Remarkably, chronic creatine treatment delayed the onset of several symptoms and, in some cases, completely abolished their appearance, supporting creatine supplementation as a useful strategy to slow the progression of MJD. \nIn summary in this work we validated a new MJD mouse model for use in preclinical trials as a powerful tool to study simultaneously pathogenic mechanisms associated with the disease and to develop novel therapeutic strategies. Furthermore, we found that Hsp90 inhibitors, TUDCA and creatine are relevant therapeutic candidates for MJD, some of which could be advanced to clinical trials in MJD patients.
Institution: University of Minho
Language: English
Open Access status: green
OpenAlex ID: W2289852391
Cites: 401
Cited by: 1
Related to: 10